Market Trends of Global Vibrating Mesh Nebulizer Industry
The COPD Segment is Expected to Witness Considerable Growth During the Forecast Period
The COPD segment is expected to exhibit a significant growth rate during the study period owing to factors such as the growing burden of COPD globally, coupled with increasing utilization of vibrating mesh nebulizers to deliver targeted therapies in COPD. Moreover, supportive government initiatives promoting awareness about COPD are expected to drive demand for respiratory devices such as vibrating mesh nebulizers, fueling market uptake.
The alarming burden of COPD is expected to fuel the adoption of vibrating mesh nebulizers to deliver targeted treatment regimens to restore damaged lung functions. For instance, according to August 2024 data from the American Lung Association, around 11.7 million, or 4.6% of adults in the United States, suffered from COPD or any of its forms in 2022. Hence, the significant burden of COPD is expected to foster market expansion over the coming years.
The segment growth is expected to be driven by the adoption of vibrating mesh nebulizers compared to jet nebulizers in treating chronic obstructive pulmonary disease. For instance, according to an article published by the International Journal of Chronic Obstructive Pulmonary Disease in March 2024, vibrating mesh nebulizers have significant drug delivery capabilities for COPD compared to jet nebulizers, and this capability has remarkably improved their adoption in the treatment of COPD. Therefore, such proven benefits of vibrating mesh nebulizers are projected to bolster their uptake, thereby driving segment expansion.
Additionally, the utilization of vibrating mesh nebulizers to deliver different classes of bronchodilators in COPD management has opened new business avenues for market uptake. For instance, in October 2022, HCmed and AeroRx used the breath-actuated nebulizer (vibrating mesh) to deliver pulmonary drugs for COPD as these nebulizers deliver doses of medicines in the form of mist when the patient inhales. Hence, such instances are anticipated to generate new business opportunities for segment expansion.
Also, the growing research funding for COPD is expected to accelerate demand for advanced respiratory devices, fueling market expansion. For example, 2024 data from the National Institute of Health shows that research funding for COPD is projected to increase to 149 million from 148 million in 2023. Hence, increasing research funding is expected to bolster industry growth over the coming years.
Therefore, the factors mentioned above, such as the growing burden of COPD and the utilization of vibrating mesh nebulizers in COPD, are expected to drive segment market growth.
North America is Expected to Witness Considerable Growth During the Forecast Period
North America is expected to hold a significant market share in the vibrating mesh nebulizer market due to factors such as the increasing prevalence of respiratory disorders in the region and the growing adoption of technologically advanced nebulizers. In addition, growing awareness for vibrating mesh nebulizers in home care settings is projected to support regional market growth over the coming years.
The growing burden of asthma in North America is expected to support market growth. For instance, according to data published by the Asthma and Allergy Foundation of America in September 2023, more than 27 million people in the United States had asthma. In addition, around 10.8% of female adults had asthma, compared to 6.5% of male adults in 2023. Therefore, the significant burden of respiratory disease in North America is expected to bolster market expansion during the study period.
Also, supportive reimbursement policies for respiratory devices, mainly vibrating mesh nebulizers, are anticipated to create significant opportunities in the market. For example, data from the United States Centers for Medicare & Medicaid Services in January 2024, nebulizers, including vibrating mesh models, are covered under the Durable Medical Equipment (DME) benefit. These favorable reimbursement policies are projected to enhance product utilization, supporting industry growth.
Moreover, supportive reimbursement policies for respiratory devices, including vibrating mesh nebulizers, are projected to offer potential opportunities in the market. For instance, according to January 2024 data from the United States Centers for Medicare & Medicaid Services, nebulizers, including vibrating mesh nebulizers, are covered under its Durable Medical Equipment (DME) benefit. Hence, the supportive reimbursement policies are expected to accelerate the utilization of these products, thereby driving regional market growth.
Additionally, ongoing investigational studies using vibrating mesh nebulizers in the United States are expected to boost regional market expansion. For instance, according to September 2024 data from ClinicalTrial.Gov, four active studies are investigating the administration of lung therapeutics through vibrating mesh nebulizer delivery. Hence, such ongoing investigational studies will drive regional market growth during the study period.
Hence, the above factors are expected to drive the North American market during the forecast period.
